Multiple myeloma (MM) is a hematological malignancy that remains incurable because most
patients will eventually relapse or become refractory to the treatments. Although the …

Recently, several advances have been made in understanding the pathogenesis of multiple
myeloma. Increasing evidence favours a pre-switched, but somatically mutated B-cell as …

Introduction: The development of proteasome inhibitor (PI) and immunomodulatory drugs
(IMiDs) and advances in supportive care have considerably changed the treatment …

Multiple myeloma (MM) remains an incurable hematologic malignancy characterized by
frequent early responses, inevitably followed by treatment relapse. Until recently, few …

The past decade has witnessed a dramatic improvement in the therapeutic options in
multiple myeloma (MM). Several novel biologically targeted agents are in clinical use and …

Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematologic cancer. MM is characterized by the accumulation of malignant plasma cells …

The therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last
15 years with the advent of immunomodulatory drugs and proteasome inhibitors. However …

Multiple myeloma (MM) is a clonal plasma cell malignancy clinically characterized by
osteolytic lesions, immunodeficiency, and renal disease. There are an estimated 750,000 …

In vitro and in vivo models have been developed that have allowed for delineation of
mechanisms of multiple myeloma (MM) cell homing to bone marrow (BM); tumor cell …

Introduction: The introduction of autologous stem cell transplantation as well as novel agents
such as proteasome inhibitors (bortezomib) and immunomodulatory drugs (IMiDs; …